131 related articles for article (PubMed ID: 10719867)
1. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
Remsen LG; Trail PA; Hellström I; Hellström KE; Neuwelt EA
Neurosurgery; 2000 Mar; 46(3):704-9. PubMed ID: 10719867
[TBL] [Abstract][Full Text] [Related]
2. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.
Muldoon LL; Neuwelt EA
J Neurooncol; 2003 Oct; 65(1):49-62. PubMed ID: 14649885
[TBL] [Abstract][Full Text] [Related]
3. Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model.
Remsen LG; Marquez C; Garcia R; Thrun LA; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1045-9. PubMed ID: 11704329
[TBL] [Abstract][Full Text] [Related]
4. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Hofstead S; Casazza AM; Firestone RA; Hellström I; Hellström KE
Science; 1993 Jul; 261(5118):212-5. PubMed ID: 8327892
[TBL] [Abstract][Full Text] [Related]
5. Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats.
Muldoon LL
Neurosurgery; 2003 Dec; 53(6):1406-12; discussion 1412-3. PubMed ID: 14633307
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
[TBL] [Abstract][Full Text] [Related]
8. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
[TBL] [Abstract][Full Text] [Related]
10. Development and activities of the BR96-doxorubicin immunoconjugate.
Hellström I; Hellström KE; Senter PD
Methods Mol Biol; 2001; 166():3-16. PubMed ID: 11217374
[No Abstract] [Full Text] [Related]
11. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
Tolcher AW; Sugarman S; Gelmon KA; Cohen R; Saleh M; Isaacs C; Young L; Healey D; Onetto N; Slichenmyer W
J Clin Oncol; 1999 Feb; 17(2):478-84. PubMed ID: 10080588
[TBL] [Abstract][Full Text] [Related]
13. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
[TBL] [Abstract][Full Text] [Related]
14. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
[TBL] [Abstract][Full Text] [Related]
15. Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.
Neuwelt EA; Barnett PA; McCormick CI; Remsen LG; Kroll RA; Sexton G
Clin Cancer Res; 1998 Jun; 4(6):1549-55. PubMed ID: 9626476
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of CC49-doxorubicin immunoconjugates.
Johnson DA; Briggs SL; Gutowski MC; Barton R
Anticancer Res; 1995; 15(4):1387-93. PubMed ID: 7654026
[TBL] [Abstract][Full Text] [Related]
17. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
19. Stabilization of chimeric BR96-doxorubicin immunoconjugate.
Barbour NP; Paborji M; Alexander TC; Coppola WP; Bogardus JB
Pharm Res; 1995 Feb; 12(2):215-22. PubMed ID: 7784336
[TBL] [Abstract][Full Text] [Related]
20. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
